Psoriasis Clinical Trial

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

Summary

This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects receiving tildrakizumab injections at Week 0, Week 4, Week 16, Week 28, Week 40, and Week 52. The total study duration will be approximately 64 weeks, excluding a screening period.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects are non-immunocompromised males or females 18 years of age or older.
Subjects have ≥3% total body surface area plaque psoriasis.
Subjects are candidates for phototherapy or systemic therapy.
Subject must be diagnosed at least 6 months prior to entering the study.
Females must be surgically sterile, postmenopausal for >5 years, or using a highly effective form of birth control (<1% failure rate), for at least 30 days prior to test article exposure, with a negative serum pregnancy test.

Exclusion Criteria:

Subject is pregnant, lactating, or is planning to become pregnant during the study.
Subject is younger than 18 years of age.
Subjects with uncontrolled mental illness or active suicidal ideations based on baseline mental health questionnaire of choice.
Subject is known, or suspected of being unable to comply with the study protocol, in the opinion of the investigator.
Subject is currently enrolled in an investigational drug or device study.

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

55

Study ID:

NCT03718299

Recruitment Status:

Completed

Sponsor:

Sun Pharmaceutical Industries Limited

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Therapeutics Clinical Research
San Diego California, 92123, United States
Site 02
Grandville Michigan, 49418, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

55

Study ID:

NCT03718299

Recruitment Status:

Completed

Sponsor:


Sun Pharmaceutical Industries Limited

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.